Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266716 · ClinicalTrials.gov registry record · NA
Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder
A NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT05266716: Completed NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.
NCT05266716 is a NA study of Methamphetamine Abuse that has completed, run by Affect Therapeutics. The registered enrollment target is 79 participants, below the 204-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05266716, a NA study of Methamphetamine Abuse, has completed, sponsored by Affect Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of the Affect app that enhance engagement of participants in the study toward the goal of improving patient outcomes, including reduction/cessation of stimulant use.
Primary Outcome
Consistent with general approaches to measure retention (Hser et al., 2004, McLellan et al., 2006), the outcome will be based on completion as a binary measure at the end of the planned 8-week intervention for each participant. At the end-of-program telephone interview, participants will be deemed to be either treatment completers (i.e., retained) or dropouts (not retained if out of program before the end of week 4). Termination, expulsion, or unexplained non-response to or no contact with Affec
Conditions Studied
Interventions
- BEHAVIORAL Affect Methamphetamine Treatment Program
Study Locations (1)
New York
- Affect Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2022-01-07 |
| Phase | NA |
What the finished NCT05266716 record still lists
NCT05266716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 204-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Methamphetamine Abuse appearing as the primary indexed condition, and to 1 intervention - of which Affect Methamphetamine Treatment Program is the first listed.
NCT05266716 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05266716 about?
NCT05266716 is a clinical study titled "Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder". The overall purpose of the observational, investigational pilot study is to assess the clinical utility of the Affect digital health platform (the Affect® "app") as part of the Affect program of treatment for methamphetamine-primary stimulant use disorder. The study also will identify elements of th...
What is the current status of trial NCT05266716?
This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2021-02-18. Estimated completion is 2022-01-07.
What conditions does trial NCT05266716 study?
This clinical trial studies the following conditions: Methamphetamine Abuse.
What interventions are being tested in trial NCT05266716?
The interventions under investigation include: Affect Methamphetamine Treatment Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05266716?
This trial is sponsored by Affect Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05266716 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05266716's enrollment target sits among peer trials
79 9th of 15 higher than 7 of 15 other Methamphetamine Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Theta Burst TMS for Treatment of Methamphetamine Use Disorder
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Mood and Decision-making in Methamphetamine Use Disorder
RECRUITING · NA
-
Contingency Management for Drug Use: Does Age Matter?
ACTIVE NOT RECRUITING · NA
-
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI